arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Adicet Bio, Inc.

ACET
$8.45 ▼ -0.79 (-8.55%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
39 Visible periods
20 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

Adicet Bio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $90.8M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -18.7% ↘
FCF / Share $-1.86 ↗
Trailing P/E —
Price / Book 0.7x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

39-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-20.24M
↑ +28.2% —
FCF / Share Free cash flow per share
$-1.86
↑ +7.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
12
Financial Health ↓
2
Cash Quality ↓
56

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 10 years · 39 quarters